Cook Medical has introduced the BIGopsy Backloading Biopsy Forceps, a device designed to obtain large renal or ureteral tissue specimens up to 4 mm3 for cancer diagnosis.
We have recently published a focus on kidney cancer that will be available for free until July 8th and we thought it may be of interest to members of the Kidney Cancer Association. Free login is required. There are several types of kidney cancerrenal cell carcinoma (RCC) is the most common. Traditionally resistant to radiation and conventional chemotherapy, invasive surgery has been the mainstay of treatment.
Real-time MRI-guided radiation therapy using an MRI-accelerator might become a valuable non-invasive alternative to the current RCC treatment options.
Eighth Annual Penn State Uplifting Athletes "Lift For Life" Set for July 9 to Benefit the Kidney Cancer Association
Penn State Football Uplifting Athletes announced today that the 2010 Lift for Life is set for Friday, July 9. with doors to Holuba Hall opening at 1:30 p.m. Proceeds again will benefit the Kidney Cancer Association.
Robotic and laparoscopic partial nephrectomy is a treatment option for small renal masses (less than 4cm). During the procedure, clamping of the renal vessels is required to minimize bleeding. This video presents a technique utilizing hemostatic hydrodissection and bipolar and radio frequency coagulation to avoid renal vascular clamping and renal ischemia.
Importance of Comorbidity in Competing Risks Analysis in Patients With Localized Renal Cell Carcinoma
Although Kutikov et al1 recognize the importance of comorbidity for understanding why older patients may have a higher probability of dying from other causes than dying from RCC, unfortunately their nomogram does not take comorbidity into account to reach additional precision in the prediction of the different probabilities of dying. Comorbidity is important as predictor of survival in RCC, especially in localized tumors.2 Multivariate analysis in other studies indicated that besides tumor stage, grade, and size of the tumor, comorbidity has a significant predictive value on overall survival.
Role of Cytoreductive Nephrectomy Remains Unclear in Targeted Therapy Era; Retrospective Analysis Suggests Benefit
Patients with metastatic renal cell carcinoma (RCC) who undergo cytoreductive nephrectomy prior to treatment with VEGF-targeted therapy may have longer overall survival than patients who do not have surgery, according to a relatively large retrospective analysis presented here at the Genitourinary Cancers Symposium. Experts at the multidisciplinary meeting cosponsored by ASCO, ASTRO, and the Society of Urologic Oncology, however, emphasized the need for prospective randomized trials to definitively answer the question and described trials already ongoing in Europe.
AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday. These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEOs highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).
U.S. scientists at the Mayo and Cleveland clinics say they've found blood flow interruption during kidney cancer surgery can lead to chronic kidney disease.
The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma